160 related articles for article (PubMed ID: 34969874)
1. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
[TBL] [Abstract][Full Text] [Related]
2. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
3. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
4. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
[TBL] [Abstract][Full Text] [Related]
6. Low disease activity state in juvenile-onset systemic lupus erythematosus.
Ozturk K; Caglayan S; Tanatar A; Baglan E; Yener Otar G; Kavrul Kayaalp G; Karadag SG; Demir F; Sonmez HE; Ozdel S; Cakan M; Aktay Ayaz N; Sozeri B;
Lupus; 2021 Nov; 30(13):2144-2150. PubMed ID: 34723709
[TBL] [Abstract][Full Text] [Related]
7. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study.
Wang L; Liang X; Cao Z; Wang D; Luo Y; Feng Y; Luo C; Zhi S; Huang Y; Fan Z; Wang C; Liu H; Liu J; Zhang T; Cheng Q; Xie X; Shuai L; Rong Z; Zeng P; Yu H; Lu M; Sun L; Yang S; Zhao D; Zhang W; Wu X; Li Q; Wang Y; Zhang Q; Yang J; Li X; Song H; Tang X
Rheumatology (Oxford); 2024 May; 63(5):1437-1446. PubMed ID: 37606970
[TBL] [Abstract][Full Text] [Related]
9. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
[TBL] [Abstract][Full Text] [Related]
10. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).
Babaoglu H; Li J; Goldman D; Magder LS; Petri M
Lupus; 2019 Dec; 28(14):1648-1655. PubMed ID: 31694446
[TBL] [Abstract][Full Text] [Related]
11. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
Pawlak-Buś K; Schmidt W; Leszczyński P
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
[TBL] [Abstract][Full Text] [Related]
12. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
[TBL] [Abstract][Full Text] [Related]
13. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
[TBL] [Abstract][Full Text] [Related]
14. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
15. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
Yoshida M; Minowa K; Amano H; Asai Y; Yamaji K; Tamura N
Lupus; 2021 Aug; 30(9):1378-1384. PubMed ID: 33966540
[TBL] [Abstract][Full Text] [Related]
16. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
Abdelhady EI; Rabie M; Hassan RA
Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE.
Cody EM; Wilson BE; Ogbu EA; Huggins JL; Chen C; Qiu T; Ting TV; Flores F; Huang B; Brunner HI
Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37253553
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study.
Wang D; Shan C; Liu J; Zhang R; Zhu G; Gao T; Chang H; Gao S; Bai C; Nie N; Zhang Q; Lin Y
Front Immunol; 2022; 13():1067721. PubMed ID: 36591249
[TBL] [Abstract][Full Text] [Related]
19. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Morand EF; Abreu G; Furie RA; Golder V; Tummala R
Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
[TBL] [Abstract][Full Text] [Related]
20. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
